Several major pharmaceutical companies, including Pfizer, Bristol Myers Squibb and Sanofi, are set to raise prices on more than 250 branded medications in the U.S. starting Jan. 1, 2025, according to a Reuter's exclusive report. 

A new GLP-1 generic is entering the U.S. market amid ongoing debates about cost, access and innovation within this increasingly popular drug class.

The FDA approved a subcutaneous injection version of Bristol Myers Squibb nivolumab and hyaluronidase-nvhy for the treatment of several cancers including melanoma, non-small cell lung cancer and renal cell carcinoma. 

The ERISA Industry Committee has filed a lawsuit in the U.S. District Court for the District of Minnesota, challenging the state's Pharmacy Benefit Manager Licensure and Regulation Act. 

A growing push to ban pharmaceutical ads on U.S. television faces significant hurdles, despite vocal support among key figures in the incoming Trump administration, The New York Times reported Dec. 23. 

Two-and-a-half years after President Joe Biden signed the Inflation Reduction Act into law, Medicare Part D beneficiaries will soon see an annual cap on medication costs. 

After a priority review, the FDA did not approve an injectable form of Rybrevant, a Johnson & Johnson medication for non-small cell lung cancer. 

An Illinois drugmaker is voluntarily recalling lots of two medications for organ transplant rejection because bottles may contain empty bottles.

The FDA has granted its fast-track designation to an experimental vaccine for Staphylococcus aureus. 

A GLP-2 drug candidate from Zealand Pharma failed to garner FDA approval as the regulatory agency asked for an additional trial to confirm the medication's efficacy and safety.